APP Pharmaceuticals Inc

APP Pharmaceuticals — American Pharmaceutical Partners — Merger or Acquisition (November 2005)

36 slides from APP Pharmaceuticals's merger presentation, Nov 29, 2005

  1. Slide 1: Introducing Abraxis BioScience Transforming APP

    Introducing Abraxis BioScience Transforming APP Exhibit 99.2 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements The statements contained in this Presentation that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Because these forward-looking statements involve risks and uncertainties, the

  3. Slide 3: Fully-Integrated Biopharma Company Transforming APP and Introducing Abraxis BioScience

    3 Hospital-Based Portfolio Discovery Platform Deep Pipeline Manufacturing & Infrastructure Fully-Integrated Biopharma Company Transforming APP and Introducing Abraxis BioScience Abraxis BioScience APP Manufacturing Injectable Portfolio & Pipeline Sales & Marketing Global ABRAXANE ® nab ™ Platform/ I

  4. Slide 4: Strategic Rationale for Combining APP and ABI

    4 Strategic Rationale for Combining APP and ABI Unite complementary capabilities of APP and ABI Consolidate global ABRAXANE ® sales and profits for current and potential future indications Gain access to ABI’s deep pipeline of oncology and critical care therapeutics Leverage APP’s existing proprieta

  5. Slide 5: Consolidating Strengths of APP and ABI

    5 Consolidating Strengths of APP and ABI Oncology, critical care and anti- infective injectable portfolio and pipeline 50% North America ABRAXANE ® profits Leading product market shares, with over two-thirds of products ranked #1 or 2 Unique commercial scale nanoparticle manufacturing capabilities T

  6. Slide 6: Abraxis BioScience: Best of Biotech, Injectables and Pharma in an Integrated Company

    6 Abraxis BioScience: Pursuing the Best of Biotech, Injectables and Pharma in an Integrated Company Abraxis BioScience Breakthrough Science Rapid Clinical Development Deep Pipeline Manufacturing Infrastructure Hospital-Based Distribution Strong Cash Flow Proprietary Product Platform Global Scope Sal

  7. Slide 7: Consolidating Strengths into a Profitable, Fully-Integrated, Global Biopharma Company

    7 Discovery Engine Clinical Development Deep Pipeline Manufacturing Capability Global Sales Management Infrastructure nab ™ Platform & SPARC Strong IP ABRAXANE ® (74 Clinical Trials) Discovery & Development Global Regulatory e-filing Taiho Japan Natural Product & Analogue Library CGMP Phase I - III

  8. Slide 8: A Profitable Biopharmaceutical Company With Breadth, Depth and Global Scope

    8 Santa Monica, CA Richmond Hill, Ontario Tokyo, Japan ( Taiho ) Taiho ) ) United Kingdom Schaumburg, IL Melrose Park, IL Barbengo, Switzerland Beijing, China Grand Island, NY Australia ( Alchemia ) Alchemia ) ) Auburn, CA Facilities Partners Worldwide injectable manufacturing >200mm vials annually

  9. Slide 9: Transaction Summary

    9 Transaction Summary 100% stock-for-stock tax-free merger of ABI into APP APP to issue approximately 86 million additional APP shares to ABI shareholders Combined market value of approximately $7.5 billion* ABI shareholders to own 83.5% of Abraxis BioScience from 64.4% Special Committee of APP Boar

  10. Slide 10: Transaction Summary (cont'd)

    10 Transaction Summary (cont’d) Corporate governance and voting agreement signed by P. Soon-Shiong, MD APP Special Committee – Goldman, Sachs & Co.; Gibson Dunn & Crutcher LLP APP – Morrison & Foerster LLP ABI – Merrill Lynch & Co.; Lazard Ltd.; Fried, Frank, Harris, Shriver & Jacobson LLP Expected

  11. Slide 11: Simplified Ownership Structure

    11 Simplified Ownership Structure ABI APP 50% N.A. ABRAXANE ® Injectables Portfolio & Pipeline 50% N.A. & ROW ABRAXANE ® Abraxis BioScience WW ABRAXANE ® Injectables Portfolio & Pipeline Pre-Transaction Post-Transaction nab ™ Platform & Pipeline nab ™ Platform & Pipeline ABI Shareholders APP Public

  12. Slide 12: Fully-Integrated Biopharma Company Transforming APP

    12 Fully-Integrated Biopharma Company Transforming APP and Introducing Abraxis BioScience Abraxis BioScience APP Manufacturing Injectable Portfolio & Pipeline Sales & Marketing Global ABRAXANE ® nab TM Platform/ IP Proprietary Pipeline ABI R&D & Regulatory Infrastructure N.A. ABRAXANE ® Global ABRAX

  13. Slide 13: ABRAXANE: The Next Generation Taxane

    13 No Premedication Required Double Response Rate vs Taxol in MBC Prolonged Time To Tumor Progression Prolonged Survival in 2 nd line MBC Rapid Resolution of Peripheral Neuropathy No Increased Toxicity in Elderly Patients Reduced Myelosuppression Higher Paclitaxel Dose Shorter Infusion Duration Stan

  14. Slide 14: ABRAXANE Highly Successful Launch

    14 Approved in January 2005 for 2 nd + Line MBC Taxane 2nd+ Line MBC total patient share over 22% in September* Taxotere and paclitaxel shares down 15% and 7%, respectively, January to September* Unique J code issued, effective January 1, 2006 $796 list price/WAC, Medicare reimbursement at WAC+6% Th

  15. Slide 15: ABRAXANE Clinical Development Plan Redefining the Taxane Market

    15 ABRAXANE ® Clinical Development Plan Redefining the Taxane Market Dosage per cycle Taxane activity in new tumor types Increased number of cycles Combination therapy Avastin ® , Herceptin ® Head and neck, melanoma, taxane refractory Weekly vs 3-weekly Longer TTP Current U.S. Taxane Market Size: 32

  16. Slide 16: ABRAXANE Clinical Development Plan

    16 2005 1 initiated, 4 planned studies 3 planned studies 2 initiated, 10 planned studies 2 initiated, 4 planned studies 1 initiated, 4 planned studies 3 initiated, 12 planned studies 4 initiated, 6 planned studies 7 initiated, 11 planned studies A B R A X A N E ABRAXANE ® Clinical Development Plan 7

  17. Slide 17: Significant Global Market Potential for ABRAXANE

    17 Significant Global Market Potential for ABRAXANE ® 2005 United States A B R A X A N E ® Canada Mexico NSCLC Prostate Melanoma Pancreatic Ovary NSCLC Prostate Melanoma Pancreatic Ovary NSCLC Prostate Melanoma Pancreatic Ovary Europe NSCL Prostate Melanoma Pancreatic Ovary China NSCLC Prostate Mela

  18. Slide 18: Global ABRAXANE / Discovery Platform / Deep Pipeline

    18 Global ABRAXANE ® Discovery Platform Deep Pipeline Fully-Integrated Biopharma Company Transforming APP and Introducing Abraxis BioScience Abraxis BioScience APP Manufacturing Injectable Portfolio & Pipeline Sales & Marketing Proprietary Pipeline ABI R&D & Regulatory Infrastructure N.A. ABRAXANE ®

  19. Slide 19: The nab Platform: Pipeline Strategy

    19 ABRAXANE ® nab ™ -docetaxel nab ™ -17AAG nab ™ -mTor Inhibitor Novel Oral Seco-Taxane nab ™ -17AAG Analogs Radicicol / Analogs nab ™ -Thiocolchicine dimers HKP Targeting CD13 Combretastatins The nab TM Platform: Pipeline Strategy Deep oncology pipeline 6 INDs to be filed in 2006/2007 Over 20 NCEs

  20. Slide 20: Targeting the Tumor and its Microenvironment: nab-SPARC Platform

    20 Targeting the Tumor and its Microenvironment nab ™ - SPARC Platform Tumor Secreted SPARC Albumin- Bound Paclitaxel Albumin-activated gp60 Receptor

  21. Slide 21: Proprietary Natural Product Library: A Source of New Chemical Entities

    21 Proprietary Natural Product Library: A Source of New Chemical Entities (NCEs) ABI Chemically Diverse Strain Collection

  22. Slide 22: Oncology Pipeline Targeting Multiple Molecular Targets

    22 Oncology Pipeline Targeting Multiple Molecular Targets 2005 MBC NSCLC Prostate cancer • In combination with ABRAXANE ® • Other phase II trials for single agent activity • In combination with ABRAXANE ® • Multiple myeloma • Other phase II trials for single agent activity • Colorectal carcinoma • O

  23. Slide 23: Critical Care Pipeline

    23 Critical Care Pipeline 2005 Coronary Artery Restenosis Hemodialysis Peripheral Artery Restenosis Anti-Thrombin Inhibitor Coronary Artery Restenosis Anesthetic • 64 critical care products on the market • 26 critical care products in development Low Molecular Wt. Heparin Low Molecular Wt. Heparin A

  24. Slide 24: Hospital-Based Portfolio

    24 Discovery Platform Deep Pipeline Hospital-Based Portfolio Fully-Integrated Biopharma Company Transforming APP and Introducing Abraxis BioScience Abraxis BioScience APP Manufacturing Injectable Portfolio & Pipeline Sales & Marketing Global ABRAXANE ® Proprietary Pipeline ABI R&D & Regulatory Infra

  25. Slide 25: Injectables Portfolio Touches Every Aspect of Hospital Care

    25 Vascular Anti-nauseant Cardiac Gastrointestinal Hemostatics Hormones Psychotherapeutics Vitamins Neurologic Anesthetic Analgesic Therapeutic Category 2005 2004 2003 2002 2001 2000 Source: IMS 2004 12 11 10 5 APP Comp #1 Comp #2 Comp #3 Comp #4 Source: Q3 2005 IMS (Bags and Vials) Source: Q3 2005

  26. Slide 26: Strong History of Injectables Product Approvals and Robust Product Pipeline

    26 Strong History of Injectables Product Approvals and Robust Product Pipeline Source: CDER 2001-Q3 2005. Excludes tentative approvals. 16 15 13 23 ANDAs/NDAs Pending at FDA Development Stage Feasibility Stage Stability/ Pre-Filing APP is among the leaders in product approvals APP has 67 products in

  27. Slide 27: Track Record of High Growth and Profitability

    27 $65.9 $136.5 $165.5 $192.0 $277.5 $351.3 $405.0 $500.0+ $0 $50 $100 $150 $200 $250 $300 $350 $400 $450 $500 1998 1999 2000 2001 IPO 2002 2003 2004 2005E Track Record of High Growth and Profitability Goal of > 50% gross margin achieved in 2003 54.5% 36.7% 49.4% 53.3% 36.2% 33.3% 26.0% Revenues/ Gr

  28. Slide 28: Manufacturing & Infrastructure

    28 Discovery Platform Deep Pipeline Hospital-Based Portfolio Manufacturing & Infrastructure Fully-Integrated Biopharma Company Transforming APP and Introducing Abraxis BioScience Abraxis BioScience APP Manufacturing Injectable Portfolio & Pipeline Sales & Marketing Global ABRAXANE ® Proprietary Pipe

  29. Slide 29: Research, Clinical & Regulatory Capabilities

    29 Research, Clinical & Regulatory Capabilities Drug discovery and synthesis Preclinical efficacy models Drug formulation Animal toxicology Early phase drug manufacturing Regulatory affairs Medical affairs Global IND filings Clinical operations Biostatistics and data management Oracle ® clinical wit

  30. Slide 30: Unique Commercial Scale Nanoparticle Manufacturing Capabilities

    30 Unique Commercial Scale Nanoparticle Manufacturing Capabilities Melrose Park, IL and Grand Island, NY, Only commercial scale protein- engineered nanoparticle manufacturing capacity in the U.S. Currently produce 200 million vials of product per year Over $120 million invested in manufacturing faci

  31. Slide 31: Proprietary Drug Sales & Marketing Capabilities

    31 Proprietary Drug Sales & Marketing Capabilities Marketing to leading U.S. oncologists 130 employees including: 85 experienced sales representatives 15 Regional and National Sales Account Executives 10 Medical Science Liaisons 5 Reimbursement Specialists 15 Marketing/other Professionals 5 5 6 7 10

  32. Slide 32: Realizing the Value and Globalization of ABRAXANE

    32 Realizing the Value and Globalization of ABRAXANE ® Abraxis BioScience Provides a Clear Path to: Establishing a Leadership in Oncology via nab ™ Pipeline and SPARC Launching a Profitable, Fully-Integrated, Global Oncology and Critical Care Biopharma Company with Revenues Exceeding $500M, a Season

  33. Slide 33: Financial Strengths

    33 Financial Strengths Combined company expected to continue to have positive operating cash flow Opportunity for sustained high growth and enhanced long-term profitability and shareholder value ABI brings its share of North America profits and ROW marketing rights to ABRAXANE ® ABI brings multiple

  34. Slide 34: Abraxis BioScience: Fully-Integrated Biopharmaceutical Company with Deep Pipeline

    34 Abraxis BioScience: Fully-Integrated Biopharmaceutical Company with Deep Pipeline nab TM Platform & SPARC Proprietary Pipeline Injectable Portfolio & Pipeline Global ABRAXANE ® Business Assets Therapeutic Areas Infrastructure Capabilities Commercial R&D Manufacturing Regulatory Oncology Critical

  35. Slide 35: ABRAXANE for Injectable Suspension indication

    AXbraxane’ for Injectable Suspension (paclitaxel protein-Nound partic albumin-hound ABRAXANE for I treatment of brea es for injectable suspension) jectable Suspension is indicated forthe st cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant

  36. Slide 36: ABRAXANE safety information

    Abraxane’ for Injectable Suspension (paclitaxel protein-tound particles tor injectable suspension) (elbumin-baund} In the randomized metastatic breast cancer study, the most important adverse events included neutropenia (all cases 80%; severe 9%), anemia (all 33%; severe 1%), infections (24%), senso

American Pharmaceutical Partners — Merger or Acquisition (November 2005) on 6ix